Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab versus placebo in eosinophilic frequent-exacerbating COPD
NL-OMON44215Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Oct 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mepolizumab in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by GSK. Primary endpoint: Frequency of moderate to severe exacerbations. Started Oct 2014; status: active, not recruiting.
02
Drugs
mepolizumab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON44215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44215.